Adaptive Treatment for Smoking, Cessation

Phase-Based Progress Estimates
Smoking, Cessation
Adaptive Treatment - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will test how well a machine learning-based intervention can help people quit smoking.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 4-weeks after quit day

4-weeks after quit day
Number of patients who quit smoking as confirmed by absence of salivary cotinine

Trial Safety

Trial Design

2 Treatment Groups

Usual care
1 of 2
Adaptive Treatment plus usual care
1 of 2
Active Control
Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Adaptive Treatment · No Placebo Group · N/A

Adaptive Treatment plus usual careExperimental Group · 4 Interventions: interviewing-based counseling, Adaptive Treatment, Android Wear smartwatch, Nicotine Patch · Intervention Types: Behavioral, Behavioral, Behavioral, Drug
Usual careActiveComparator Group · 3 Interventions: interviewing-based counseling, Android Wear smartwatch, Nicotine Patch · Intervention Types: Behavioral, Behavioral, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4-weeks after quit day

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,225 Previous Clinical Trials
5,612,867 Total Patients Enrolled
72 Trials studying Smoking, Cessation
19,566 Patients Enrolled for Smoking, Cessation
The University of Texas Health Science Center, HoustonLead Sponsor
799 Previous Clinical Trials
249,999 Total Patients Enrolled
8 Trials studying Smoking, Cessation
863 Patients Enrolled for Smoking, Cessation
Emily Hebert, DrPHPrincipal InvestigatorThe University of Texas Health Science Center, Houston

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have no contraindications to using NRT.
Participants must have an Android smartphone with a screen size of 5.2 inches or larger, and be willing to install the InsightTM mHealth app on their phone.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
The University of Texas Health Science Center at Houston100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%